June 22, 2017
Please join Fitch, Even, Tabin & Flannery LLP for a complimentary webinar, “The Difficulties of Being Obvious: Practical Advice for Overcoming Obviousness Rejections,” on Thursday, June 22, 2017, at 9:00 am PDT / 10:00 am MDT / 11:00 am CDT / 12:00 noon EDT.
In the predictable arts, an obviousness rejection is typically based on a combination of multiple references. Attempting to overcome such a rejection can be a perplexing and frustrating experience. This is particularly true when the patent examiner is combining references to arrive at the claimed invention in what can be a highly subjective manner. Nevertheless, when it comes time to respond, there will usually be more than one way to get the job done.
Our webinar will address best practices for responding to obviousness rejections, covering these topics and more:
- How to take the prevailing and latest Federal Circuit case law into account in your responses
- Making effective claim amendments specifically tailored to overcome the obviousness rejection
- Developing persuasive arguments in support of patentability over a combination of references
Our speakers will be Fitch Even partner Stephen S. Favakeh and patent agent Thomas A. James. For over 25 years, Steve has assisted clients with the strategic procurement and enforcement of patent and trademark rights in the U.S. and abroad, with a special focus on Japanese clients. He drafts and prosecutes patent applications as well as advises clients on IP portfolios and licensing programs, among other services.
Tom prepares and prosecutes patent applications in addition to assisting with litigation matters. He was previously a patent examiner with the U.S. Patent and Trademark Office, working primarily in the field of electrical engineering.
IP Alert | Stock Ownership Leads to Vacatur of $2.75B District Court JudgmentAugust 8, 2022
On June 23, in Centripetal Networks v. Cisco Systems, the Federal Circuit vacated judgment of the district court because stock held by the judge's wife violated the recusal statute and was not harmless error. Read more
IP Alert | Rehearing Reverses Earlier Federal Circuit Decision Finding Silence Supported Negative Claim LimitationJuly 6, 2022
On June 21, in Novartis Pharmaceuticals Corporation v. Accord Healthcare, Inc., a reshuffled Federal Circuit panel reversed course on rehearing to find that a negative claim limitation was not supported by silence in the patent's specification. Read more